Fulgent Genetics Inc Revenue Growth Rates (FLGT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Fulgent Genetics Inc   (NASDAQ: FLGT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

FLGT's Revenue Growth by Quarter and Year

Fulgent Genetics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FLGT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 85.39
1st Quarter March 70.49
FY 155.88

FLGTs Annual Revenue
Fulgent Genetics Inc 's Revenue in the fiscal year 2025 $ 321.88 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2024 $ 283.22 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2023 $ 288.46 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2022 $ 618.97 millions
Fulgent Genetics Inc 's Revenue in the fiscal year 2021 $ 992.58 millions




FLGT Revenue second quarter 2026 Y/Y Growth Comment
Fulgent Genetics Inc reported Revenue growth of 4.85% year on year in the second quarter 2026, to $ 85.39 millions, this is lower than Fulgent Genetics Inc 's recent average Revenue surge of 245.49%.

Looking into second quarter 2026 results within Medical Laboratories industry 21 other companies have achieved higher Revenue growth. While Fulgent Genetics Inc ' s Revenue increase of 4.85% ranks overall at the positon no. 2259 in the second quarter 2026.


FLGT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 7.36 % 9.85 % 4.68 %
3rd Quarter September - 18 % -15.59 % -20.65 %
2nd Quarter June 4.85 % 15.53 % 4.32 % -46.09 %
1st Quarter March -3.9 % 14.43 % -3.13 % -79.34 %
FY   - 13.65 % -1.82 % -

Financial Statements
Fulgent Genetics Inc 's second quarter 2026 Revenue $ 85.39 millions FLGT's Income Statement
Fulgent Genetics Inc 's second quarter 2025 Revenue $ 81.44 millions Quarterly FLGT's Income Statement


FLGT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 0.08 % 10 % -15.47 %
3rd Quarter September - 2.54 % 0.4 % 24.08 %
2nd Quarter June 21.14 % 11.03 % 9.97 % 2.12 %
1st Quarter March -15.66 % -5.78 % -9.55 % -2.26 %
FY (Year on Year)   - 13.65 % -1.82 % -


Back to FLGT Growth rate Comparisons >> Back to FLGT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #335
Overall #2259

Revenue Y/Y Growth Statistics
High Average Low
4536 % 245.49 % -79.34 %
(Mar 31 2021)   (Jun 30 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #335
Overall #2259
Revenue Y/Y Growth Statistics
High Average Low
4536 % 245.49 % -79.34 %
(Mar 31 2021)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Fulgent Genetics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
489.15 % 21.51 % -60.86 %
(Sep 30 2020)  


FLGT's II. Quarter Q/Q Revenue Comment
Fulgent Genetics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 21.14% quarter on quarter, to $ 85.39 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 11.03% in the II. Quarter a year ago.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Fulgent Genetics Inc 's Revenue growth quarter on quarter, overall rank is 492.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #97
Overall #492
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #97
Overall #492
Revenue Q/Q Growth Statistics
High Average Low
489.15 % 21.51 % -60.86 %
(Sep 30 2020)  


FLGT's II. Quarter Q/Q Revenue Comment
Fulgent Genetics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 21.14% quarter on quarter, to $ 85.39 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 11.03% in the II. Quarter a year ago.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Fulgent Genetics Inc 's Revenue growth quarter on quarter, overall rank is 492.


Fulgent Genetics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 322.97 $ 319.02 $ 321.88 $ 316.14 $ 303.40
Y / Y Revenue Growth (TTM) 6.45 % 9.08 % 13.65 % 14.45 % 4.87 %
Year on Year Revenue Growth Overall Ranking # 2083 # 1992 # 1812 # 1134 # 1589
Seqeuential Revenue Change (TTM) 1.24 % -0.89 % 1.81 % 4.2 % 3.74 %
Seq. Revenue Growth (TTM) Overall Ranking # 2217 # 1887 # 1493 # 2033 # 1256


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Fulgent Genetics Inc 's cumulative twelve months Revenue were $ 323 millions, company would post below average annual Revenue growth of 3.74% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Fulgent Genetics Inc 's Revenue growth from the 70.49% growth in Mar 31 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1992 to 2083.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 312
Overall # 2083

Revenue TTM Y/Y Growth Statistics
High Average Low
2115.31 %
 172.43 %
-66.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 326
S&P 500 # 2217
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Fulgent Genetics Inc 's cumulative twelve months Revenue were $ 323 millions, company would post below average annual Revenue growth of -66.81% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Fulgent Genetics Inc 's Revenue growth from the 70.49% growth in Mar 31 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1992 to 2083.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 312
Overall # 2083

Revenue TTM Y/Y Growth Statistics
High Average Low
2115.31 %
172.43 %
-66.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 326
S&P 500 # 2217




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FLGT's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions
Addus Homecare Corp8.18%$ 8.181 millions
Puma Biotechnology Inc 7.75%$ 7.754 millions
Cryoport inc 7.74%$ 7.737 millions
Schrodinger Inc 7.54%$ 7.542 millions
Boston Scientific Corporation7.53%$ 7.528 millions
Agilon Health Inc 7.15%$ 7.151 millions
Tenet Healthcare Corp6.77%$ 6.773 millions
Henry Schein Inc 6.73%$ 6.728 millions
Collegium Pharmaceutical Inc 6.67%$ 6.668 millions
Mallinckrodt Plc6.62%$ 6.617 millions
Johnson and Johnson6.60%$ 6.600 millions
Prestige Consumer Healthcare Inc 6.57%$ 6.569 millions
Msa Safety Inc6.25%$ 6.252 millions
Pacira Biosciences inc 6.24%$ 6.240 millions
Globus Medical Inc 5.94%$ 5.940 millions
Labcorp Holdings Inc 5.78%$ 5.778 millions
Tandem Diabetes Care Inc 5.77%$ 5.768 millions
Bristol myers Squibb Company5.74%$ 5.738 millions
Haemonetics Corporation5.65%$ 5.646 millions
Progyny Inc 5.58%$ 5.584 millions
Cytek Biosciences Inc 5.57%$ 5.566 millions
Amphastar Pharmaceuticals Inc 5.44%$ 5.441 millions
Becton Dickinson And Company5.44%$ 5.438 millions
Bruker Corporation5.22%$ 5.220 millions
Davita Inc 5.17%$ 5.165 millions


About Fulgent Genetics Inc Revenue Growth Rates (FLGT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Fulgent Genetics Inc (CIK 1674930).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-326136
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Fulgent Genetics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.